Breaking News

Artis BioSolutions Establishes Synthetic DNA Mfg. Hub in Boston 

Expanded facility integrates Syngoi Technologies’ enzymatic DNA platform into Artis’ North American operations.

Artis BioSolutions, an advanced therapies company integrating specialized technologies, infrastructure, and manufacturing capabilities for next-gen genetic medicines, established new synthetic DNA manufacturing capabilities in Boston utilizing Syngoi Technologies’ enzymatic platform.  This expansion strategically extends Artis’ regional capabilities, integrating with its advanced therapy development and GMP manufacturing facility in Watertown, MA, to deliver reliable, scalable, services to it...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters